ABSTRACT
Clinicians and basic researchers worldwide convened at the annual Digestive Disease Week where the latest research in the field of gastroenterology and hepatology is presented. In this report, the highlights of the convention on the field of Barrett's esophagus (BE) and associated esophageal adenocarcinoma (EAC) are summarized. New clinical and preclinical developments in etiology, diagnosis, surveillance, and prevention and therapy of BE and EAC in respect to current knowledge are reflected. We also discuss the relevance and impact of these findings on the future of BE and EAC research.
Subject(s)
Adenocarcinoma , Barrett Esophagus , Esophageal Neoplasms , Adenocarcinoma/diagnosis , Adenocarcinoma/etiology , Adenocarcinoma/metabolism , Adenocarcinoma/therapy , Barrett Esophagus/diagnosis , Barrett Esophagus/etiology , Barrett Esophagus/metabolism , Barrett Esophagus/therapy , Biomarkers/metabolism , Biopsy , Disease Progression , Esophageal Neoplasms/diagnosis , Esophageal Neoplasms/etiology , Esophageal Neoplasms/metabolism , Esophageal Neoplasms/therapy , Esophagectomy , Esophagoscopy , Esophagus/pathology , Gastrointestinal Agents/therapeutic use , Humans , Risk FactorsABSTRACT
The course of disease and the predictive value of depression and anxiety in patients with migraine were prospectively examined. We recruited 393 migraineurs through articles in newspapers and performed a follow-up examination 30 months later. At baseline and follow-up, patients underwent a semistructured interview, filled out the Headache Impact Test (HIT-6), Self-rating Depression Scale (SDS) and Self-rating Anxiety Scale (SAS) and they kept a headache diary for 30 days. One hundred and fifty-one patients (38.6%) were seen at follow-up. The baseline data of patients with and without follow-up were comparable. At follow-up the number of headache days per month had decreased from 9.6 +/- 5.8 to 8.1 +/- 6.3 (P < 0.001) and the proportion of patients with chronic headache (15.4%) and medication overuse (13%) had remained stable. SDS and SAS scores were associated with a high migraine frequency and high initial SDS scores predicted high migraine frequency at follow-up. This longitudinal study in unselected patients with migraine not excluding subjects with chronic headache, medication overuse, depression or anxiety does not point towards migraine as a progressive disease in the vast majority of patients and confirms the importance of psychiatric comorbidity.